Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Global Perspectives on     Industrial BiotechnologyInternational Bioenergy Summit 2012November 5-6 2012Yali Friedman, Ph.D...
Global Biotechnology Global Biotechnology Overview  Location matters  • Workforce cost, availability  • Access to skilled ...
Global Biotechnology  Technology producers vs. consumers  Innovators           • Products tailored          • Gain foreign...
Global Biotechnology    Strong market opportunities drive innovation  Why is the U.S. the world leader in biotechnology?  ...
Global Biotechnology                  Developing Country                     Perspective  Case Study: Philippines  • Limit...
Global Biotechnology                 Acquiring Medicines  Develop a domestic drug development industry  • Pros: Can develo...
Global BiotechnologySolution: Produce foreign drugs locally  Weak patent laws enable domestic production of    drugs devel...
Global Biotechnology   Costs of Weak Patent Protection  India (mostly) adopts TRIPS accords in 1995  • Amends patent laws ...
Global Biotechnology   Who benefits from not patenting Glivec?  Novartis provides Glivec free to most patients in India  •...
Global Biotechnology   Overcoming weak/poor markets  Mectizan  • River blindness drug developed by Merck  • Affected indiv...
Global Biotechnology Meeting national needs: Economic Development                        Three basic models  India, Brazil...
Measuring Global Biotechnology       www.saworldview.com                             www.CommercialBiotechnology.com
Biotechnology is a Global Industry                          www.CommercialBiotechnology.com
Measuring innovation capacity                       www.CommercialBiotechnology.com
Top and Bottom                 www.CommercialBiotechnology.com
Brain drain              www.CommercialBiotechnology.com
University-Industry Collaboration                          www.CommercialBiotechnology.com
Agricultural Biotechnology                     www.CommercialBiotechnology.com
Biotechnology paper output                     www.CommercialBiotechnology.com
Higher Prices = Faster Access                       www.CommercialBiotechnology.com
Innovation is still in legacy pharma countries                                     www.CommercialBiotechnology.com
IP and R&D             www.CommercialBiotechnology.com
Bottom line• Internal development or external? Innovation or duplication   – Patent policy must be aligned with goals• Bui...
Upcoming SlideShare
Loading in …5
×

Building Biotechnology in India

2,011 views

Published on

Published in: Technology

Building Biotechnology in India

  1. 1. Global Perspectives on Industrial BiotechnologyInternational Bioenergy Summit 2012November 5-6 2012Yali Friedman, Ph.D. – info@thinkbiotech.com www.CommercialBiotechnology.com
  2. 2. Global Biotechnology Global Biotechnology Overview Location matters • Workforce cost, availability • Access to skilled management, supportive services • Proximity to innovative science and markets Who is doing what, where? www.CommercialBiotechnology.com
  3. 3. Global Biotechnology Technology producers vs. consumers Innovators • Products tailored • Gain foreign to domestic needs currency • Tax revenues • Reliant on others to from domestic develop products for domestic needs companies Followers • Non profit-enabling and workers projects are unlikely to attract investment Importers Exporters www.CommercialBiotechnology.com
  4. 4. Global Biotechnology Strong market opportunities drive innovation Why is the U.S. the world leader in biotechnology? • World’s largest market for most biotechnology products – Not divided like European countries • World’s strongest patent protection • World’s largest absolute expenditures on R&D – The U.S. once spent more on R&D than the rest of the world combined • No government price controls on drugs www.CommercialBiotechnology.com
  5. 5. Global Biotechnology Developing Country Perspective Case Study: Philippines • Limited domestic drug production capacity • Must purchase essential medicines from foreign countries with higher wage-costs (e.g. Singapore) – This is effectively reverse-offshoring • Government has a limited budget, must make difficult decisions about how much of which vaccines to buy • Domestic production would reduce costs, preserve foreign currency, keep revenues domestic, and could train workers for innovative drug development www.CommercialBiotechnology.com
  6. 6. Global Biotechnology Acquiring Medicines Develop a domestic drug development industry • Pros: Can develop drugs for domestic needs, can drive tax revenues, can derive foreign currency from exports • Cons: Expensive, takes time, requires unwavering government support Buy drugs from foreign countries • Pros: No need to invest in risky R&D, gain access to best drugs produced by global leaders • Cons: Expensive, depletes foreign currency, doesn’t generate tax revenues www.CommercialBiotechnology.com
  7. 7. Global BiotechnologySolution: Produce foreign drugs locally Weak patent laws enable domestic production of drugs developed elsewhere • Pros: Low-cost domestic production of many drugs using domestic workers, tax revenues from production and sales • Cons: Reduced foreign investment by global firms, reduced motivation to develop drugs for locally-endemic conditions www.CommercialBiotechnology.com
  8. 8. Global Biotechnology Costs of Weak Patent Protection India (mostly) adopts TRIPS accords in 1995 • Amends patent laws to protect product patents, with the notable extra criteria that new drug products must “differ significantly in properties with regard to efficacy” • In 2007 Novartis failed to obtain a patent on Glivec (sold as Gleevec in the US) • Novartis CEO: unfavorable patent ruling is “not an invitation to invest in Indian research and development.” Company will redirect hundreds of millions of dollars in investments to countries where it has greater IP protection. www.CommercialBiotechnology.com
  9. 9. Global Biotechnology Who benefits from not patenting Glivec? Novartis provides Glivec free to most patients in India • Because Indian manufacturers would be unable to compete with Novartis’ free domestic distribution, their target markets would likely be in other countries, where they could potentially erode Novartis’ market. Is India forfeiting investments from Novartis simply so that Indian companies can sell Novartis’ drugs abroad? Does this serve the public? www.CommercialBiotechnology.com
  10. 10. Global Biotechnology Overcoming weak/poor markets Mectizan • River blindness drug developed by Merck • Affected individuals unable to pay for drug, so Merck distributes the drug for free • This model is unsustainable. Doesn’t incentivize development of drugs for these conditions, instead relying on companies to support tangential discoveries. OneWorld Health, Bill & Melinda Gates Foundation, etc. • Non-profit drug company solicits foundation support to actively develop shelved drugs for neglected populations www.CommercialBiotechnology.com
  11. 11. Global Biotechnology Meeting national needs: Economic Development Three basic models India, Brazil, Thailand • Weak IP, focus on generic production and foreign sales Israel, Cuba, maybe India • Moderate IP, leverage generic production skills to develop innovative drugs Singapore, Puerto Rico • Strong IP, attract manufacturing investments from global leaders www.CommercialBiotechnology.com
  12. 12. Measuring Global Biotechnology www.saworldview.com www.CommercialBiotechnology.com
  13. 13. Biotechnology is a Global Industry www.CommercialBiotechnology.com
  14. 14. Measuring innovation capacity www.CommercialBiotechnology.com
  15. 15. Top and Bottom www.CommercialBiotechnology.com
  16. 16. Brain drain www.CommercialBiotechnology.com
  17. 17. University-Industry Collaboration www.CommercialBiotechnology.com
  18. 18. Agricultural Biotechnology www.CommercialBiotechnology.com
  19. 19. Biotechnology paper output www.CommercialBiotechnology.com
  20. 20. Higher Prices = Faster Access www.CommercialBiotechnology.com
  21. 21. Innovation is still in legacy pharma countries www.CommercialBiotechnology.com
  22. 22. IP and R&D www.CommercialBiotechnology.com
  23. 23. Bottom line• Internal development or external? Innovation or duplication – Patent policy must be aligned with goals• Build strong foundations: – R&D activity – Brain drain• Support the business case – Identify global best practices with local relevance – Answer the question: Why India? Why now? www.CommercialBiotechnology.com

×